Myasthenia Gravis

Increased health care costs, use of nonsteroidal immunosuppressants, and elevated health care costs were associated with use of glucocorticoids by patients with myasthenia gravis.

The efficacy and safety of efgartigimod in pediatric patients will need to be further validated with future studies.

Patients with myasthenia gravis had a more consistent clinical response and fewer deteriorations when using add-on therapy early.

Patients with ocular myasthenia gravis (MG) should be regularly assessed to reduce the chances of progression to generalized MG.

Patients with myasthenia gravis (MG) had greater morbidity and extended hospitalization when they underwent cardiac surgery.

The serial monitoring of muscle-specific kinase (MuSK) antibodies could help in assessing the severity of the disease.

The test was more likely to have a positive response in patients with a decrement after nerve stimulation.

More than half of the young patients with myasthenia gravis (MG) responded well to the use of corticosteroids.

Empathy, knowledge, and attitudes in care for patients with myasthenia gravis were improved when using a patient-centric immersive virtual reality intervention.

A review of case studies found that patients with double seronegative myasthenia gravis (MG) had similarities in the ways their condition presented.

Minimizing the use of corticosteroids in clinical practice can help to prevent any long-term impact on patients with myasthenia gravis.

Methylprednisolone was more effective in treating thymoma compared with docetaxel but adverse effects were more common.

Patients with myasthenia gravis experience significantly higher rates of urinary incontinence and overactive bladder symptoms, impacting their quality of life.

Jonathan Strober, MD, discusses promising results from the VIBRANCE-MG trial, highlighting nipocalimab's safety and efficacy for pediatric myasthenia gravis.

Patients with generalized myasthenia gravis face significant barriers to diagnosis, creating the need for improved patient–health care interactions.

Discover the latest breakthroughs in myasthenia gravis treatment, including rozanolixizumab and nipocalimab, and insights on disease burden and dysphagia indicators.

Inebilizumab gains FDA approval for treating generalized myasthenia gravis, showing significant improvements in muscle strength and steroid reduction.

Minimally invasive thymectomy for ocular myasthenia gravis (MG) enhanced complete stable remission rates and reduced surgical risks.

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, achieving significant symptom reduction and demonstrating a novel CAR T-cell approach.

Rozanolixizumab shows promise in treating triple-seronegative myasthenia gravis, offering hope for patients with limited treatment options.

Gefurulimab shows significant improvements in myasthenia gravis (MG) symptoms, offering a convenient self-administered treatment option for patients.

Remibrutinib shows promise in treating generalized myasthenia gravis, with ongoing trials assessing its efficacy and safety for patients.

Experts discuss personalized myasthenia gravis treatment, emphasizing patient education and engagement for optimal care and advocacy in managing this variable disease.

Ratna Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD, advocate for improved proactive management of myasthenia gravis (MG) for better patient outcomes.

Thorough eye exams in patients who have myasthenia gravis can detect concurrent autoimmune retinopathy and its complications.